424 related articles for article (PubMed ID: 21119733)
1. Targeting non-malignant disorders with tyrosine kinase inhibitors.
Grimminger F; Schermuly RT; Ghofrani HA
Nat Rev Drug Discov; 2010 Dec; 9(12):956-70. PubMed ID: 21119733
[TBL] [Abstract][Full Text] [Related]
2. Combined tyrosine and serine/threonine kinase inhibition by sorafenib prevents progression of experimental pulmonary hypertension and myocardial remodeling.
Klein M; Schermuly RT; Ellinghaus P; Milting H; Riedl B; Nikolova S; Pullamsetti SS; Weissmann N; Dony E; Savai R; Ghofrani HA; Grimminger F; Busch AE; Schäfer S
Circulation; 2008 Nov; 118(20):2081-90. PubMed ID: 18955668
[TBL] [Abstract][Full Text] [Related]
3. Targeting the tyrosine kinase signalling pathways for treatment of immune-mediated glomerulonephritis: from bench to bedside and beyond.
Ma TK; McAdoo SP; Tam FW
Nephrol Dial Transplant; 2017 Jan; 32(suppl_1):i129-i138. PubMed ID: 28391340
[TBL] [Abstract][Full Text] [Related]
4. Developing target therapy against oncogenic tyrosine kinase in myeloid maliganacies.
Naoe T
Curr Pharm Biotechnol; 2006 Oct; 7(5):331-7. PubMed ID: 17076649
[TBL] [Abstract][Full Text] [Related]
5. Tyrosine kinase inhibitors and their unique therapeutic potentialities to combat cancer.
Zhao Y; Bilal M; Raza A; Khan MI; Mehmood S; Hayat U; Hassan STS; Iqbal HMN
Int J Biol Macromol; 2021 Jan; 168():22-37. PubMed ID: 33290765
[TBL] [Abstract][Full Text] [Related]
6. Nanoformulations of small molecule protein tyrosine kinases inhibitors potentiate targeted cancer therapy.
Yin Y; Yuan X; Gao H; Yang Q
Int J Pharm; 2020 Jan; 573():118785. PubMed ID: 31678384
[TBL] [Abstract][Full Text] [Related]
7. Targeting non-receptor tyrosine kinases using small molecule inhibitors: an overview of recent advances.
Hojjat-Farsangi M
J Drug Target; 2016; 24(3):192-211. PubMed ID: 26211367
[TBL] [Abstract][Full Text] [Related]
8. Pazopanib: an oral multitargeted tyrosine kinase inhibitor for use in renal cell carcinoma.
LaPlant KD; Louzon PD
Ann Pharmacother; 2010 Jun; 44(6):1054-60. PubMed ID: 20407031
[TBL] [Abstract][Full Text] [Related]
9. Targeting mutated tyrosine kinases in the therapy of myeloid leukaemias.
Banerji L; Sattler M
Expert Opin Ther Targets; 2004 Jun; 8(3):221-39. PubMed ID: 15161429
[TBL] [Abstract][Full Text] [Related]
10. Use of tyrosine kinase inhibitors for chronic myeloid leukemia: management of patients and practical applications for pharmacy practitioners.
Wong SF; Mirshahidi H
Ann Pharmacother; 2011 Jun; 45(6):787-97. PubMed ID: 21672900
[TBL] [Abstract][Full Text] [Related]
11. Novel Approaches for Efficient Delivery of Tyrosine Kinase Inhibitors.
Moradpour Z; Barghi L
J Pharm Pharm Sci; 2019; 22(1):37-48. PubMed ID: 30636671
[TBL] [Abstract][Full Text] [Related]
12. Management of dose variability and side effects for individualized cancer pharmacotherapy with tyrosine kinase inhibitors.
Terada T; Noda S; Inui K
Pharmacol Ther; 2015 Aug; 152():125-34. PubMed ID: 25976912
[TBL] [Abstract][Full Text] [Related]
13. Small molecule tyrosine kinase inhibitors in the treatment of solid tumors: an update of recent developments.
Steeghs N; Nortier JW; Gelderblom H
Ann Surg Oncol; 2007 Feb; 14(2):942-53. PubMed ID: 17103252
[TBL] [Abstract][Full Text] [Related]
14. Ponatinib-induced cardiotoxicity: delineating the signalling mechanisms and potential rescue strategies.
Singh AP; Glennon MS; Umbarkar P; Gupte M; Galindo CL; Zhang Q; Force T; Becker JR; Lal H
Cardiovasc Res; 2019 Apr; 115(5):966-977. PubMed ID: 30629146
[TBL] [Abstract][Full Text] [Related]
15. Progresses in polymeric nanoparticles for delivery of tyrosine kinase inhibitors.
Foroughi-Nia B; Barar J; Memar MY; Aghanejad A; Davaran S
Life Sci; 2021 Aug; 278():119642. PubMed ID: 34033837
[TBL] [Abstract][Full Text] [Related]
16. Potential utility of small tyrosine kinase inhibitors in the treatment of diabetes.
Mokhtari D; Welsh N
Clin Sci (Lond); 2009 Nov; 118(4):241-7. PubMed ID: 19886867
[TBL] [Abstract][Full Text] [Related]
17. Systems pharmacological analysis of mitochondrial cardiotoxicity induced by selected tyrosine kinase inhibitors.
Vaidya T; Kamta J; Chaar M; Ande A; Ait-Oudhia S
J Pharmacokinet Pharmacodyn; 2018 Jun; 45(3):401-418. PubMed ID: 29446053
[TBL] [Abstract][Full Text] [Related]
18. Targeting kinases in asthma.
Blease K
Expert Opin Investig Drugs; 2005 Oct; 14(10):1213-20. PubMed ID: 16185163
[TBL] [Abstract][Full Text] [Related]
19. Pulmonary toxicities of tyrosine kinase inhibitors.
Peerzada MM; Spiro TP; Daw HA
Clin Adv Hematol Oncol; 2011 Nov; 9(11):824-36. PubMed ID: 22252615
[TBL] [Abstract][Full Text] [Related]
20. Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action?
Gotink KJ; Verheul HM
Angiogenesis; 2010 Mar; 13(1):1-14. PubMed ID: 20012482
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
